StockNews.com Initiates Coverage on Bellerophon Therapeutics (NASDAQ:BLPH)

StockNews.com began coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH) in a research report sent to investors on Sunday. The firm issued a hold rating on the biotechnology company’s stock.

Bellerophon Therapeutics Stock Performance

Shares of BLPH stock opened at $0.06 on Friday. The firm has a fifty day simple moving average of $0.04 and a two-hundred day simple moving average of $0.05. Bellerophon Therapeutics has a 12 month low of $0.03 and a 12 month high of $0.10. The firm has a market capitalization of $672,815.00, a PE ratio of -0.07 and a beta of 0.71.

Bellerophon Therapeutics Company Profile

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.